PROCEPT BioRobotics (PRCT) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRCT shares.
View PRCT analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month target prices for PROCEPT BioRobotics' stock. Their PRCT share price forecasts range from $43.00 to $53.00. On average, they anticipate the company's stock price to reach $46.83 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts.

PROCEPT BioRobotics' stock was trading at $41.54 on January 1st, 2023. Since then, PRCT stock has decreased by 21.8% and is now trading at $32.50.
View the best growth stocks for 2023 here.

PROCEPT BioRobotics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,200,000 shares, a decline of 15.1% from the April 30th total of 2,590,000 shares. Based on an average daily volume of 403,200 shares, the days-to-cover ratio is currently 5.5 days. Approximately 5.2% of the shares of the company are sold short.
View PROCEPT BioRobotics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PRCT earnings forecast.

PROCEPT BioRobotics Co. (NASDAQ:PRCT) posted its earnings results on Thursday, April, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.04. The business earned $24.40 million during the quarter, compared to analysts' expectations of $24.32 million. PROCEPT BioRobotics had a negative trailing twelve-month return on equity of 45.87% and a negative net margin of 115.53%. PROCEPT BioRobotics's quarterly revenue was up 71.8% on a year-over-year basis. During the same period last year, the company posted ($0.39) earnings per share.

ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), ALPS Disruptive Technologies ETF (DTEC), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ), Principal Healthcare Innovators ETF (BTEC), First Trust Small Cap Growth AlphaDEX Fund (FYC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Invesco DWA SmallCap Momentum ETF (DWAS) and

PROCEPT BioRobotics issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.00 million-$128.00 million, compared to the consensus revenue estimate of $126.71 million.

(PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share.

PROCEPT BioRobotics trades on the NASDAQ under the ticker symbol "PRCT."

PROCEPT BioRobotics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (4.21%), Price T Rowe Associates Inc. MD (2.98%), State Street Corp (1.77%), Geode Capital Management LLC (1.32%) and Frank Rimerman Advisors LLC (1.01%). Insiders that own company stock include Alaleh Nouri, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel.
View institutional ownership trends.

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRCT stock can currently be purchased for approximately $32.50.

PROCEPT BioRobotics (NASDAQ:PRCT) has a market capitalization of $1.46 billion and generates $75.01 million in revenue each year. The company earns $-87,150,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

The company employs 234 workers across the globe.

PROCEPT BioRobotics' mailing address is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. The official website for the company is www.procept-biorobotics.com. The company can be reached via phone at 650-232-7200 or via email at ir@procept-biorobotics.com.